Comprehensive Stock Comparison
Compare Mineralys Therapeutics, Inc. (MLYS) vs ADMA Biologics, Inc. (ADMA) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Stability / Safety | MLYS | Beta 0.40 vs ADMA's 1.10 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | MLYS | +220.1% vs ADMA's -5.0% |
| Efficiency (ROA) | ADMA | 36.8% ROA vs MLYS's -28.6%, ROIC 37.7% vs -107.3% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Mineralys Therapeutics is a clinical-stage biopharmaceutical company developing novel treatments for hypertension and cardiovascular diseases. It generates no revenue currently but aims to monetize its lead candidate lorundrostat — a selective aldosterone synthase inhibitor — through future drug approvals and commercialization. The company's competitive advantage lies in its targeted approach to aldosterone inhibition, which addresses a specific biological pathway in treatment-resistant hypertension.
ADMA Biologics is a biopharmaceutical company that develops, manufactures, and markets specialty plasma-derived biologics for treating immune deficiencies and infectious diseases. It generates revenue primarily from sales of its intravenous immune globulin products — BIVIGAM and ASCENIV — along with its Hepatitis B treatment Nabi-HB, while also operating plasma collection facilities. The company's key advantage is its integrated business model that combines plasma collection, manufacturing, and commercialization, creating a vertically controlled supply chain for plasma-derived therapies.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
MLYS leads in 3 of 6 categories (Financial Metrics, Valuation Metrics). ADMA leads in 2 (Profitability & Efficiency, Total Returns).
Financial Metrics (TTM)
ADMA and MLYS operate at a comparable scale, with $489M and $0 in trailing revenue.
| Metric | MLYSMineralys Therape… | ADMAADMA Biologics, I… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $489M |
| EBITDAEarnings before interest/tax | -$184M | $175M |
| Net IncomeAfter-tax profit | -$171M | $209M |
| Free Cash FlowCash after capex | -$171M | $41M |
| Gross MarginGross profit ÷ Revenue | — | +54.7% |
| Operating MarginEBIT ÷ Revenue | — | +34.2% |
| Net MarginNet income ÷ Revenue | — | +42.9% |
| FCF MarginFCF ÷ Revenue | — | +8.3% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +12.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +54.0% | 0.0% |
Valuation Metrics
| Metric | MLYSMineralys Therape… | ADMAADMA Biologics, I… |
|---|---|---|
| Market CapShares × price | $2.3B | $3.7B |
| Enterprise ValueMkt cap + debt − cash | $2.2B | $3.7B |
| Trailing P/EPrice ÷ TTM EPS | -7.99x | 19.22x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 16.30x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | 25.10x |
| Price / SalesMarket cap ÷ Revenue | — | 8.70x |
| Price / BookPrice ÷ Book value/share | 7.43x | 10.86x |
| Price / FCFMarket cap ÷ FCF | — | 33.71x |
Profitability & Efficiency
ADMA delivers a 48.6% return on equity — every $100 of shareholder capital generates $49 in annual profit, vs $-30 for MLYS. On the Piotroski fundamental quality scale (0–9), ADMA scores 7/9 vs MLYS's 1/9, reflecting strong financial health.
| Metric | MLYSMineralys Therape… | ADMAADMA Biologics, I… |
|---|---|---|
| ROE (TTM)Return on equity | -29.7% | +48.6% |
| ROA (TTM)Return on assets | -28.6% | +36.8% |
| ROICReturn on invested capital | -107.3% | +37.7% |
| ROCEReturn on capital employed | -89.0% | +39.0% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 7 |
| Debt / EquityFinancial leverage | — | 0.24x |
| Net DebtTotal debt minus cash | -$114M | -$21M |
| Cash & Equiv.Liquid assets | $114M | $103M |
| Total DebtShort + long-term debt | $0 | $82M |
| Interest CoverageEBIT ÷ Interest expense | — | 19.63x |
Total Returns (with DRIP)
A $10,000 investment in ADMA five years ago would be worth $64,339 today (with dividends reinvested), compared to $15,868 for MLYS. Over the past 12 months, MLYS leads with a +220.1% total return vs ADMA's -5.0%. The 3-year compound annual growth rate (CAGR) favors ADMA at 63.7% vs MLYS's 18.1% — a key indicator of consistent wealth creation.
| Metric | MLYSMineralys Therape… | ADMAADMA Biologics, I… |
|---|---|---|
| YTD ReturnYear-to-date | -18.1% | -12.9% |
| 1-Year ReturnPast 12 months | +220.1% | -5.0% |
| 3-Year ReturnCumulative with dividends | +64.6% | +338.6% |
| 5-Year ReturnCumulative with dividends | +58.7% | +543.4% |
| 10-Year ReturnCumulative with dividends | +58.7% | +227.8% |
| CAGR (3Y)Annualised 3-year return | +18.1% | +63.7% |
Risk & Volatility
MLYS is the less volatile stock with a 0.40 beta — it tends to amplify market swings less than ADMA's 1.10 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.
| Metric | MLYSMineralys Therape… | ADMAADMA Biologics, I… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.40x | 1.10x |
| 52-Week HighHighest price in past year | $47.65 | $25.67 |
| 52-Week LowLowest price in past year | $8.69 | $13.50 |
| % of 52W HighCurrent price vs 52-week peak | +61.4% | +60.7% |
| RSI (14)Momentum oscillator 0–100 | 43.5 | 35.7 |
| Avg Volume (50D)Average daily shares traded | 1.0M | 1.8M |
Analyst Outlook
Wall Street rates MLYS as "Buy" and ADMA as "Buy". Consensus price targets imply 77.7% upside for MLYS (target: $52) vs 2.8% for ADMA (target: $16).
| Metric | MLYSMineralys Therape… | ADMAADMA Biologics, I… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $52.00 | $16.00 |
| # AnalystsCovering analysts | 8 | 9 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 1 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Feb 23 | Feb 26 | Change |
|---|---|---|---|
| Mineralys Therapeut… (MLYS) | 100 | 167.41 | +67.4% |
| ADMA Biologics, Inc. (ADMA) | 100 | 492.96 | +393.0% |
ADMA Biologics, Inc. (ADMA) returned +543% over 5 years vs Mineralys Therapeut… (MLYS)'s +59%. A $10,000 investment in ADMA 5 years ago would be worth $64,339 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Mineralys Therapeut… (MLYS) | $0.00 | $0.00 | — |
| ADMA Biologics, Inc. (ADMA) | $7M | $426M | +5841.4% |
ADMA Biologics, Inc.'s revenue grew from $7M (2015) to $426M (2024) — a 57.4% CAGR.
Chart 3EPS Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Mineralys Therapeut… (MLYS) | -0.74 | -3.66 | -394.6% |
| ADMA Biologics, Inc. (ADMA) | -1.73 | 0.81 | +146.8% |
ADMA Biologics, Inc.'s EPS grew from $-1.73 (2015) to $0.81 (2024).
Chart 4Free Cash Flow — 5 Years
Mineralys Therapeutics, Inc. generated $-166M FCF in 2024 (-1043% vs 2021). ADMA Biologics, Inc. generated $110M FCF in 2024 (+187% vs 2021).
MLYS vs ADMA: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is MLYS or ADMA a better buy right now?
ADMA Biologics, Inc. (ADMA) offers the better valuation at 19.2x trailing P/E (16.3x forward), making it the more compelling value choice. Analysts rate Mineralys Therapeutics, Inc. (MLYS) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — MLYS or ADMA?
Over the past 5 years, ADMA Biologics, Inc. (ADMA) delivered a total return of +543.4%, compared to +58.7% for Mineralys Therapeutics, Inc. (MLYS). A $10,000 investment in ADMA five years ago would be worth approximately $64K today (assuming dividends reinvested). Over 10 years, the gap is even starker: ADMA returned +227.8% versus MLYS's +58.7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — MLYS or ADMA?
By beta (market sensitivity over 5 years), Mineralys Therapeutics, Inc. (MLYS) is the lower-risk stock at 0.40β versus ADMA Biologics, Inc.'s 1.10β — meaning ADMA is approximately 177% more volatile than MLYS relative to the S&P 500.
04Which has better profit margins — MLYS or ADMA?
ADMA Biologics, Inc. (ADMA) is the more profitable company, earning 46.4% net margin versus 0.0% for Mineralys Therapeutics, Inc. — meaning it keeps 46.4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ADMA leads at 32.6% versus 0.0% for MLYS. At the gross margin level — before operating expenses — ADMA leads at 51.5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Is MLYS or ADMA more undervalued right now?
Analyst consensus price targets imply the most upside for MLYS: 77.7% to $52.00.
06Which pays a better dividend — MLYS or ADMA?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is MLYS or ADMA better for a retirement portfolio?
For long-horizon retirement investors, Mineralys Therapeutics, Inc. (MLYS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.40)). Both have compounded well over 10 years (MLYS: +58.7%, ADMA: +227.8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between MLYS and ADMA?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.